Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

373 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial.
Gheorghiade M, Greene SJ, Butler J, Filippatos G, Lam CS, Maggioni AP, Ponikowski P, Shah SJ, Solomon SD, Kraigher-Krainer E, Samano ET, Müller K, Roessig L, Pieske B; SOCRATES-REDUCED Investigators and Coordinators. Gheorghiade M, et al. Among authors: greene sj. JAMA. 2015 Dec 1;314(21):2251-62. doi: 10.1001/jama.2015.15734. JAMA. 2015. PMID: 26547357 Clinical Trial.
Soluble guanylate cyclase: a potential therapeutic target for heart failure.
Gheorghiade M, Marti CN, Sabbah HN, Roessig L, Greene SJ, Böhm M, Burnett JC, Campia U, Cleland JG, Collins SP, Fonarow GC, Levy PD, Metra M, Pitt B, Ponikowski P, Sato N, Voors AA, Stasch JP, Butler J; Academic Research Team in Heart Failure (ART-HF). Gheorghiade M, et al. Among authors: greene sj. Heart Fail Rev. 2013 Mar;18(2):123-34. doi: 10.1007/s10741-012-9323-1. Heart Fail Rev. 2013. PMID: 22622468 Review.
Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes.
Gheorghiade M, Greene SJ, Filippatos G, Erdmann E, Ferrari R, Levy PD, Maggioni A, Nowack C, Mebazaa A; COMPOSE Investigators and Coordinators. Gheorghiade M, et al. Among authors: greene sj. Eur J Heart Fail. 2012 Sep;14(9):1056-66. doi: 10.1093/eurjhf/hfs093. Epub 2012 Jun 19. Eur J Heart Fail. 2012. PMID: 22713287 Free article. Clinical Trial.
Anticoagulation in heart failure: current status and future direction.
Gheorghiade M, Vaduganathan M, Fonarow GC, Greene SJ, Greenberg BH, Liu PP, Massie BM, Mehra MR, Metra M, Zannad F, Cleland JG, van Veldhuisen DJ, Shah AN, Butler J. Gheorghiade M, et al. Among authors: greene sj. Heart Fail Rev. 2013 Nov;18(6):797-813. doi: 10.1007/s10741-012-9343-x. Heart Fail Rev. 2013. PMID: 22987320 Review.
Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
Vaduganathan M, Ambrosy AP, Greene SJ, Mentz RJ, Subacius HP, Maggioni AP, Swedberg K, Nodari S, Zannad F, Konstam MA, Butler J, Gheorghiade M; EVEREST trial investigators. Vaduganathan M, et al. Among authors: greene sj. Circ Heart Fail. 2012 Nov;5(6):750-8. doi: 10.1161/CIRCHEARTFAILURE.112.970525. Epub 2012 Oct 9. Circ Heart Fail. 2012. PMID: 23051949 Clinical Trial.
Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions.
Gheorghiade M, Vaduganathan M, Greene SJ, Mentz RJ, Adams KF Jr, Anker SD, Arnold M, Baschiera F, Cleland JG, Cotter G, Fonarow GC, Giordano C, Metra M, Misselwitz F, Mühlhofer E, Nodari S, Frank Peacock W, Pieske BM, Sabbah HN, Sato N, Shah MR, Stockbridge NL, Teerlink JR, van Veldhuisen DJ, Zalewski A, Zannad F, Butler J. Gheorghiade M, et al. Among authors: greene sj. Heart Fail Rev. 2014 Mar;19(2):135-52. doi: 10.1007/s10741-012-9361-8. Heart Fail Rev. 2014. PMID: 23099992 Free PMC article.
Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial).
Greene SJ, Vaduganathan M, Lupi L, Ambrosy AP, Mentz RJ, Konstam MA, Nodari S, Subacius HP, Fonarow GC, Bonow RO, Gheorghiade M; EVEREST Trial Investigators. Greene SJ, et al. Am J Cardiol. 2013 Feb 15;111(4):574-81. doi: 10.1016/j.amjcard.2012.10.042. Epub 2012 Dec 1. Am J Cardiol. 2013. PMID: 23206923 Clinical Trial.
Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
Lanfear DE, Sabbah HN, Goldsmith SR, Greene SJ, Ambrosy AP, Fought AJ, Kwasny MJ, Swedberg K, Yancy CW, Konstam MA, Maggioni AP, Zannad F, Gheorghiade M; EVEREST trial investigators. Lanfear DE, et al. Among authors: greene sj. Circ Heart Fail. 2013 Jan;6(1):47-52. doi: 10.1161/CIRCHEARTFAILURE.112.970012. Epub 2012 Dec 12. Circ Heart Fail. 2013. PMID: 23239836 Free PMC article. Clinical Trial.
373 results